168 related articles for article (PubMed ID: 34616831)
21. Nontyphoidal
Saddler K; Castro-Lainez MT; Deliz-Aguirre R; Muñoz J; Aguilar Espinal JA; Sierra-Hoffman M; Chandna H; Howel A; Midturi J; Winn R
IDCases; 2019; 15():e00500. PubMed ID: 30788216
[TBL] [Abstract][Full Text] [Related]
22. Hemorrhagic Pericardial Effusion as the Presenting Symptom of Newly Diagnosed Rheumatoid Arthritis.
Basile EJ; Thompson I; Rafa O; Hanna ME; Sareen NJ
Cureus; 2022 Nov; 14(11):e31123. PubMed ID: 36479412
[TBL] [Abstract][Full Text] [Related]
23. [Long-term follow-up of inflammatory bowel disease patients receiving anti-tumor necrosis factor-alpha therapy].
Bacsur P; Skribanek S; Milassin Á; Farkas K; Bor R; Fábián A; Rutka M; Bálint A; Szántó KJ; Tóth T; Nagy F; Szepes Z; Boda K; Molnár T
Orv Hetil; 2020 Nov; 161(47):1989-1994. PubMed ID: 33226355
[TBL] [Abstract][Full Text] [Related]
24. Heart failure as an adverse effect of infliximab for Crohn's disease: A case report and review of the literature.
Grillo TG; Almeida LR; Beraldo RF; Marcondes MB; Queiróz DAR; da Silva DL; Quera R; Baima JP; Saad-Hossne R; Sassaki LY
World J Clin Cases; 2021 Nov; 9(33):10382-10391. PubMed ID: 34904114
[TBL] [Abstract][Full Text] [Related]
25. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
Gagniere C; Beaugerie L; Pariente B; Seksik P; Amiot A; Abitbol V; Allez M; Cosnes J; Sokol H
J Crohns Colitis; 2015 Apr; 9(4):349-55. PubMed ID: 25547977
[TBL] [Abstract][Full Text] [Related]
26. Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease.
Beltrán B; Iborra M; Sáez-González E; Marqués-Miñana MR; Moret I; Cerrillo E; Tortosa L; Bastida G; Hinojosa J; Poveda-Andrés JL; Nos P
Dig Dis; 2019; 37(2):108-115. PubMed ID: 30149385
[TBL] [Abstract][Full Text] [Related]
27. Large hemorrhagic pericardial effusion.
Barski L; Shalev L; Zektser M; Malada-Mazri H; Abramov D; Rafaely Y
Isr Med Assoc J; 2012 Jun; 14(6):367-71. PubMed ID: 22891398
[TBL] [Abstract][Full Text] [Related]
28. Theory based analysis of anti-inflammatory effect of infliximab on Crohn's disease.
Furuya Y; Ozeki T; Takayanagi R; Yokoyama H; Okuyama K; Yamada Y
Drug Metab Pharmacokinet; 2007 Feb; 22(1):20-5. PubMed ID: 17329907
[TBL] [Abstract][Full Text] [Related]
29. Large Unilateral Pleural Effusion with Pacemaker-associated Post-cardiac Injury Syndrome.
Kumar S; Madanieh A; Patel H; Srinivasa Murthy R; Goyos JM; Milunski MR
Cureus; 2018 Jul; 10(7):e2946. PubMed ID: 30397560
[TBL] [Abstract][Full Text] [Related]
30. Effects of visceral adipose tissue on anti-tumour necrosis factor-α in Crohn's disease.
Li K; Gong P; Zhang Y; Liu M; Zhang Z; Yu X; Ye M; Tian L
Therap Adv Gastroenterol; 2023; 16():17562848231171962. PubMed ID: 37168400
[TBL] [Abstract][Full Text] [Related]
31. Successful use of infliximab and tacrolimus in a patient with Crohn's disease.
Cortes X; Borrás-Blasco J; Rodríguez J; Moreno M; Molés JR; Castera E
Int J Clin Pharmacol Ther; 2015 Aug; 53(8):692-6. PubMed ID: 25997551
[TBL] [Abstract][Full Text] [Related]
32. Massive pericardial effusion without cardiac tamponade due to subclinical hypothyroidism (Hashimoto's disease).
Papakonstantinou PE; Gourniezakis N; Skiadas C; Patrianakos A; Gikas A
Rural Remote Health; 2018 May; 18(2):4384. PubMed ID: 29778090
[TBL] [Abstract][Full Text] [Related]
33. Acute Influenza Infection Presenting with Cardiac Tamponade: A Case Report and Review of Literature.
Pandey Y; Hasan R; Joshi KP; Habash FJ; Jagana R
Perm J; 2019; 23():18-104. PubMed ID: 30624200
[TBL] [Abstract][Full Text] [Related]
34. SARS-CoV-2 Complicated by a Large Hemorrhagic Pericardial Effusion.
Abdelsayed N; Mckinney B; Carter M
Cureus; 2022 Feb; 14(2):e22282. PubMed ID: 35350491
[TBL] [Abstract][Full Text] [Related]
35. Coxsackie B viral infection presenting with hemorrhagic pericardial effusion and pleural effusion.
Maram KP; Kudumula V; Paturi VRR
Ann Pediatr Cardiol; 2022; 15(1):87-89. PubMed ID: 35847405
[TBL] [Abstract][Full Text] [Related]
36. Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience.
Olivera P; Thiriet L; Luc A; Baumann C; Danese S; Peyrin-Biroulet L
Inflamm Bowel Dis; 2017 Jun; 23(6):976-985. PubMed ID: 28333755
[TBL] [Abstract][Full Text] [Related]
37. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
Gisbert JP; Marín AC; McNicholl AG; Chaparro M
Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884
[TBL] [Abstract][Full Text] [Related]
38. Postoperative therapy with infliximab for Crohn's disease: a 2-year prospective randomized multicenter study in Japan.
Fukushima K; Sugita A; Futami K; Takahashi KI; Motoya S; Kimura H; Yoshikawa S; Kinouchi Y; Iijima H; Endo K; Hibi T; Watanabe M; Sasaki I; Suzuki Y;
Surg Today; 2018 Jun; 48(6):584-590. PubMed ID: 29383596
[TBL] [Abstract][Full Text] [Related]
39. Newly diagnosed primary hypothyroidism applicant with massive pericardial effusion and acute renal failure.
Ates I; Kaplan M; Yilmaz N
Endocr Regul; 2016 Jan; 50(1):24-6. PubMed ID: 27560633
[TBL] [Abstract][Full Text] [Related]
40. Long-term clinical outcome after infliximab discontinuation in patients with inflammatory bowel disease.
Lee JM; Kim YJ; Lee KM; Yoon H; Lee BI; Kim DB; Kang D
Scand J Gastroenterol; 2018; 53(10-11):1280-1285. PubMed ID: 30351977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
